Epigenomics Ag Stock Today
| EPGNF Stock | USD 0.79 0.00 0.00% |
Performance0 of 100
| Odds Of DistressLess than 41
|
Epigenomics is trading at 0.79 as of the 1st of February 2025. This is a No Change since the beginning of the trading day. The stock's lowest day price was 0.79. Epigenomics has about a 41 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 2nd of January 2025 and ending today, the 1st of February 2025. Click here to learn more.
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. Epigenomics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. The company has 4.09 M outstanding shares. More on Epigenomics AG
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Epigenomics Pink Sheet Highlights
| CEO Board | Gregory Hamilton |
| Business Concentration | Diagnostics & Research, Healthcare (View all Sectors) |
Epigenomics AG [EPGNF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.01 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Epigenomics's market, we take the total number of its shares issued and multiply it by Epigenomics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Epigenomics AG classifies itself under Healthcare sector and is part of Diagnostics & Research industry. The entity has 4.09 M outstanding shares.
Epigenomics AG has accumulated about 15.77 M in cash with (4.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Epigenomics Probability Of Bankruptcy
Ownership AllocationEpigenomics AG retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.
Check Epigenomics Ownership Details
Epigenomics Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Epigenomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
Other Information on Investing in Epigenomics Pink Sheet
Epigenomics financial ratios help investors to determine whether Epigenomics Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Epigenomics with respect to the benefits of owning Epigenomics security.